Related Experiment Video
Updated: May 30, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Genistein inhibits osteolytic bone metastasis and enhances bone mineral in nude mice
Yanyan Zhang1, Guoying Zhu, Shuzhu Gu
1Department of Environmental Epidemiology and Bone Toxicology, Institute of Radiation Medicine, Fudan University, No. 2094 Xietu Road, Shanghai 200032, China.
Abstract:
In this study, the effective activity of genistein on osteolytic bone metastasis and bone mineral was investigated. Female BALB/c-nu/nu mice were injected with estrogen receptor-negative human breast cancer cells, MDA-MB-231, into left cardiac ventricle to form osteolytic bone metastases, and administered genistein subcutaneously after radiologically small but defined osteolytic metastases had been observed (protocol 1), simultaneously with cancer cells inoculation (protocol 2) and prophylactically 7 days before inoculation of cancer cells (protocol 3). In all protocols, genistein (10mg/kg/day) markedly reduced the number and volume of osteolytic bone metastases assessed by radiography and the number of osteoclasts. Furthermore, histomorphometrical analysis revealed that genistein markedly increased trabecular area (Tb.Ar%), trabecular thickness (Tb.Th) and trabecular number (Tb.N), and decreased trabecular separation (Tb.Sp). These results thus demonstrate that genistein could inhibit osteolytic bone metastases, suppress bone resorption, increase bone mass and improve bone microstructure in bone metastases of breast cancer.
Insights
Genistein effectively combats osteolytic bone metastases from breast cancer by reducing tumor spread and osteoclast activity. This soy isoflavone also improves bone mineral density and microstructure, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Pharmacology
- Bone Biology
Background:
- Osteolytic bone metastasis is a common complication of breast cancer, leading to significant morbidity.
- Estrogen receptor-negative breast cancer, such as MDA-MB-231, often exhibits aggressive bone metastasis.
- Genistein, a soy isoflavone, has shown potential anti-cancer and bone-protective properties.
Purpose of the Study:
- To investigate the efficacy of genistein in treating established osteolytic bone metastases.
- To evaluate genistein's impact on bone mineral density and microstructure in the context of breast cancer bone metastasis.
- To assess genistein's effects when administered therapeutically, simultaneously, or prophylactically.
Main Methods:
- Female BALB/c-nu/nu mice were inoculated with MDA-MB-231 human breast cancer cells to induce osteolytic bone metastases.
- Genistein (10mg/kg/day) was administered via subcutaneous injection across three protocols: post-metastasis observation, simultaneous with inoculation, and prophylactic.
- Radiography and histomorphometrical analysis were employed to quantify osteolytic lesions, osteoclast numbers, and bone microarchitecture parameters (trabecular area, thickness, number, separation).
Main Results:
- Genistein significantly reduced the number and volume of osteolytic bone metastases in all treatment protocols.
- A marked decrease in osteoclast numbers was observed, indicating suppression of bone resorption.
- Histomorphometry revealed significant improvements in bone microstructure, including increased trabecular area, thickness, and number, alongside decreased trabecular separation.
Conclusions:
- Genistein demonstrates potent inhibitory activity against osteolytic bone metastases in breast cancer models.
- The compound effectively suppresses bone resorption and enhances bone mass and microstructural integrity.
- Genistein presents a promising therapeutic agent for managing bone complications associated with breast cancer metastasis.
